Is Rofecoxib effective for the chemoprevention of Colorectal Adenomas?

From: Gastroenterology

Journal rating:
rating: 99%
Study Quality:
rating: 85%

Overall Reliability

Article Quality:
rating: 50%
rating: 50%


  • 2,587 subjects with a recent history of adenomas


  • Investigators randomised subjects to receive daily placebo or 25 mg rofecoxib.
  • Colonoscopic follow-up evaluation was planned for 1 and 3 years after randomisation.


  • Adenoma recurrence was less frequent for rofecoxib subjects than for those randomised to placebo (41% vs 55%; 24% reduction in risk).
  • The chemopreventive effect was more pronounced in the first year (35% reduction in risk) than in the subsequent 2 years (19% reduction in risk).
  • Rofecoxib was associated with increased risks of significant upper gastrointestinal events and serious thrombotic cardiovascular events.


  • Yes (with confidence)


Editors Notes

  • Although seen to be effective, Rofecoxib had serious side effects from its level of toxicity.